Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Neulasta (pegfilgrastim by Year
Neulasta (pegfilgrastim — Febrile Neutropenia) — Rest of World (ROW) product sales ($M) ($M)
Amgen Neulasta (pegfilgrastim: $76M in FY2025, down 32.7% from a year earlier. That is the lowest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Neulasta — ROW | 76 | (33) | % | 113 | (18) | % | 138”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neulasta (pegfilgrastim — Febrile Neutropenia) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 76 | -32.7% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 113 | -18.1% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 138 | -17.4% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 167 | -24.1% | Form 10-K (filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 220 | -24.7% | Form 10-K (filed 2023-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 292 | -28.3% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 407 | -33.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 609 | +1.0% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 603 | -16.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 723 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Neulasta (pegfilgrastim ($M), annual FY2016–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neulasta-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.